KTKim M. Tsoi

Kim M. Tsoi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kim M. Tsoi has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cell‐Free DNA as a Biomarker of Cell Death and Treatment Response for On‐Chip Three‐Dimensional Tumor Models

    by Maryam Ziaee, Julie Lafontaine, Badr Id Said, Kousha Kamal, Kim Tsoi, Francis Rodier, Thomas Gervais, Philip Wong

    On‐chip 3D cancer models are important tools to investigate treatment response and tumor biology. With their increasing adoption, there is a need for non‐destructive methods that enable the sequential monitoring of cell death and tumor response over time. This study presents quantifying cell‐free DNA (cfDNA) as a proxy for cell death for on‐chip 3D sarcoma models. qPCR analysis of media cfDNA from spheroids and micro‐dissected tumor explants (MDTs) generated from SK‐LMS‐1 and MCA‐205 cell lines cultured on microfluidic chips showed a correlation between baseline cfDNA concentration and on‐chip tumor burden. Furthermore, cfDNA levels increased in a dose‐dependent manner following cytotoxic treatments, including staurosporine and hydrogen peroxide. Single‐dose radiation therapy also raised cfDNA levels in media from MCA‐205 but not SK‐LMS‐1 MDTs, in accordance with their 2D culture response. Finally, cfDNA release within the first days of culture was shown to reflect patient‐derived MDT survival, addressing a critical unmet need for ex vivo culture. This study suggests that media cfDNA quantification could be used as a reliable, non‐disruptive, and rapidly quantifiable measure of cell death for on‐chip 3D models, which facilitates more robust use of 3D model systems for pre‐clinical assessment of treatment‐induced cell death and biological response.

  • Perivascular epithelioid cell (PEComa) tumors of the musculoskeletal system: a case series with MR imaging and histopathologic review

    by Bryan W. Buckley, Lawrence M. White, Elizabeth G. Demicco, Brendan C. Dickson, Ali Naraghi, Angela Atinga, Anthony M. Griffin, Abdulazeez Salawu, Aaron M. Gazendam, Kim M. Tsoi

  • Open Access

    Extended Curettage for Local Control of Chondromyxoid Fibroma: A 33‐Year Experience at a Single Tertiary Center

    by Liuzhe Zhang, David Clever, Aaron M. Gazendam, Anthony M. Griffin, Kim Tsoi, Peter C. Ferguson, Jay S. Wunder

    Background and Objectives: The management of chondromyxoid fibroma (CMF) primarily relies on surgical resection, but simple curettage is reportedly associated with a high local recurrence rate. While extended curettage with high‐speed burring effectively manages other locally aggressive bone tumors, its effectiveness for CMF remains unclear. We aimed to evaluate the outcome of this technique for CMF. Methods: We retrospectively reviewed 31 CMF patients treated at a single tertiary academic hospital between 1990 and 2023. Demographics and treatment details were collected. The primary outcome was local recurrence‐free survival for the patients who underwent extended curettage and had follow‐up for more than 6 months. The secondary outcome was complications. Results: The median age was 41 (IQR, 18–47), and 61% were male. Of the total 31 patients, 26 underwent extended curettage with high‐speed burring, while five underwent en bloc resection. No local recurrence occurred in either group. Among the extended curettage group, 21 had a follow‐up of more than 6 months (median follow‐up: 37 months [IQR, 18–58 months]), only one complication (symptomatic hardware removal) was recorded. Conclusions: Extended curettage with high‐speed burring was associated with excellent local control and few complications, making it a desirable surgical option for CMF.

  • Open Access

    Staged Resection with Temporizing VAC and Local Recurrence for Soft Tissue Sarcomas: A Multi-Institutional Review

    by Chloe Chose, Thomas Karadimas, Lucy Hederick, Anthony M. Griffin, Veena Jajoo, Caleb Cummings, Joseph Connolly, Thien Huong Huynh, Erik T. Newman, Kevin A. Raskin, et al.

    Background/Objectives: Staged resection with temporizing vacuum-assisted closure (VAC) has been adopted to facilitate margin assessment and local control of soft tissue sarcomas (STS). Accordingly, the objective of this study is to compare rates of local recurrence (LR) among superficial STS patients treated with and without temporizing VAC therapy. Methods: We conducted a multi-institutional retrospective cohort study of superficial STS patients treated at three tertiary care centers. Patients were matched by grade, and descriptive statistics and multivariate binary logistic regression were performed. Results: After matching, 314 superficial STS patients were included in analysis. VAC patients were more likely to present with a history of prior unplanned excision (p = 0.024), with recurrent disease (p = 0.004), harbor a diagnosis of myxofibrosarcoma (p < 0.001), and have positive initial surgical margins (p < 0.001). After multivariate analysis, VAC use remained independently associated with increased LR rates (OR = 4.117; p = 0.003). Conclusions: In this multi-institutional analysis of superficial STS patients, staged resection with temporizing VAC was not associated with improved LR rates. Rather, the VAC cohort represented distinctly higher-risk tumor biology and complex oncologic presentations, in whom the risk of LR may not be fully mitigated by surgical staging alone.

  • Clinical and magnetic resonance imaging features of soft tissue extraskeletal myxoid chondrosarcoma: A retrospective observational cohort study

    by Graham Ashburner, Shahd S. Almohsen, Elizabeth G. Demicco, Kim M. Tsoi, Jay S. Wunder, Peter C. Ferguson, Anthony M. Griffin, Ali Naraghi, Lawrence M. White

    Objectives To review the MRI, histological, and clinical features of extraskeletal myxoid chondrosarcoma (EMC). Methods Retrospective review of pre-treatment MRIs in 44 patients with pathologically proven EMC. Patient demographics, tumor MR-imaging features, histology and gene rearrangements, clinical management, and follow-up were reviewed. MRI features assessed included lesion size, location, morphology, signal characteristics, and relation to adjacent structures. Correlative analysis was performed to assess associations between demographic, clinical, molecular, and MRI variables with metastatic disease. Results EMCs were predominantly located in the lower extremity (38/44, 86%) and deep-to-fascia (36/44, 82%). All lesions (44/44) demonstrated well-circumscribed margins. Mean maximal dimension was 8.8 cm (range 1.7–36 cm); 93% (41/44) of lesions were hyperintense on fat-suppressed T2-weighted/ STIR imaging. Post-contrast enhancement was “solid” (> 80% enhancement) in 18%, “mixed” (20–80% enhancement) in 53%, and “sparse” (< 20% enhancement) in 29%. Nodal metastases were detected on preoperative imaging in four patients (9%), and pulmonary metastases in three cases preoperatively, and five cases postoperatively (range 14–128 months). EWSR1::NR4A3 fusion rearrangements were documented in 25 tumors (57%), and non-EWSR1 NR4A3 fusions in six cases (14%). The only variable demonstrating a significant correlation with metastatic disease was “solid” pattern of lesional enhancement (p = 0.035). Conclusions EMC is most commonly a deep lesion of the extremities demonstrating hyperintense T2-weighted signal, internal septations, and variable patterns of enhancement on MRI. Nodal disease is relatively frequent, and prolonged surveillance is recommended as metastases may develop years after diagnosis. Although analysis is limited by small case numbers, a “solid” (> 80%) pattern of enhancement was significantly associated with metastatic disease.

  • Open Access

    Supplementary Figure 1 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines

    by Victoria S. Coward, Jen Dorsey, Yael Babichev, Nalan Gokgoz, Andrew Seto, Anthony M. Griffin, Joshua O. Nash, Savtaj S. Brar, Peter C. Ferguson, Carol J. Swallow, et al.

    Supplementary Figure 1. A Kaplan-Meier overall survival (OS) curve based on STS type for 136 patients who gave primary specimens and had available follow up information

  • Open Access

    Supplementary Figure 2 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines

    by Victoria S. Coward, Jen Dorsey, Yael Babichev, Nalan Gokgoz, Andrew Seto, Anthony M. Griffin, Joshua O. Nash, Savtaj S. Brar, Peter C. Ferguson, Carol J. Swallow, et al.

    Supplementary Figure 2. Kaplan-Meier disease-free survival (DFS) curves for patients who gave primary specimens and did not present with recurrent disease by STS type for A) LMS (n = 55), B) MFS (n = 26), and C) UPS (n = 40) patients based on cell line growth.

  • Open Access

    Supplementary Table 4 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines

    by Victoria S. Coward, Jen Dorsey, Yael Babichev, Nalan Gokgoz, Andrew Seto, Anthony M. Griffin, Joshua O. Nash, Savtaj S. Brar, Peter C. Ferguson, Carol J. Swallow, et al.

    Supplementary Table 4. Short tandem repeat profiling of 40 cases with bulk specimens and cell line materials available for 10 loci.

  • Open Access

    Supplementary Table 2 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines

    by Victoria S. Coward, Jen Dorsey, Yael Babichev, Nalan Gokgoz, Andrew Seto, Anthony M. Griffin, Joshua O. Nash, Savtaj S. Brar, Peter C. Ferguson, Carol J. Swallow, et al.

    Supplementary Table 2. Characteristics of primary specimens used to initiate cell lines by type.

  • Open Access

    Supplementary Table 5 from Optimal Factors That Influence the Establishment of Successful Primary Human Soft-Tissue Sarcoma Cell Lines

    by Victoria S. Coward, Jen Dorsey, Yael Babichev, Nalan Gokgoz, Andrew Seto, Anthony M. Griffin, Joshua O. Nash, Savtaj S. Brar, Peter C. Ferguson, Carol J. Swallow, et al.

    Supplementary Table 5. The histology of the human primary specimens and corresponding xenograft specimens as reviewed by an expert pathologist.